ストックスクリーナーアプリを入手
2.55
0.00%
0.00
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView
KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Kiora set for Piper Sandler fireside chat on July 9 - Stock Titan
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
7EY Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiora's KIO-300 cut epileptiform activity in epilepsy model - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickStock Buy Zone - newsline.com
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Nantahala holds 148,736 shares in Kiora Pharmaceuticals (KPRX) as 3.388% stake - Stock Titan
TradingKey - TradingKey
Number of shareholders of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
EDGAR Filing Documents for 0001372514-23-000110 - SEC.gov
Kiora (NASDAQ: KPRX) details Q1 2026 results and cash runway to 2028 - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) reports Q1 loss but sees cash runway into late 2028 - Stock Titan
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Is Kiora Pharmaceuticals (KPRX) stock hiding in plain sight? (Risk Aversion) 2026-05-07Take Profit Levels - newser.com
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):